Plus Therapeutics, Inc. announced on July 23, 2025, that it received notice of an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT). This payment is part of the company’s previously awarded $17.6 million grant.
This funding provides significant non-dilutive financing, which strengthens the company's capital position for long-term growth. It reflects a strong institutional commitment to Plus Therapeutics' clinical programs.
The funds will support and accelerate the clinical development of REYOBIQ™ for the ReSPECT-LM dose optimization trial. Additionally, it will further develop the company’s CNSide LM diagnostic test as a key pivotal trial endpoint.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.